GÜRLER, F. Et Al. 2022. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. ANTI-CANCER DRUGS , vol.33, no.1 .

GÜRLER, F., Ilhan, A., GÜVEN, D. C., TURHAN, O., KURT İNCİ, B., SÜTCÜOĞLU, O., ... Yildiz, F.(2022). Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. ANTI-CANCER DRUGS , vol.33, no.1.

GÜRLER, FATİH Et Al. "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment," ANTI-CANCER DRUGS , vol.33, no.1, 2022

GÜRLER, FATİH Et Al. "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment." ANTI-CANCER DRUGS , vol.33, no.1, 2022

GÜRLER, F. Et Al. (2022) . "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment." ANTI-CANCER DRUGS , vol.33, no.1.

@article{article, author={FATİH GÜRLER Et Al. }, title={Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment}, journal={ANTI-CANCER DRUGS}, year=2022}